These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 37743972

  • 1. Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict.
    Touma H, Youssef LA, Al-Salhi L, Ismail Al-Khalil W, AlKeba K.
    Biomed Res Int; 2023; 2023():8911518. PubMed ID: 37743972
    [Abstract] [Full Text] [Related]

  • 2. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 6. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, Elalfy OM.
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 8. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
    Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C.
    Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
    [Abstract] [Full Text] [Related]

  • 9. Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review.
    Li J, Lin Y, Li X, Zhang J.
    Mediterr J Hematol Infect Dis; 2019 Oct; 11(1):e2019036. PubMed ID: 31308912
    [Abstract] [Full Text] [Related]

  • 10. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 11. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 12. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 13. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 14. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
    Tanous O, Azulay Y, Halevy R, Dujovny T, Swartz N, Colodner R, Koren A, Levin C.
    BMC Nephrol; 2021 Dec 20; 22(1):418. PubMed ID: 34930156
    [Abstract] [Full Text] [Related]

  • 15. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C, Viprakasit V, Narkbunnam N, Vathana N, Phuakpet K, Pongtanakul B, Sanpakit K, Buaboonnam J.
    Pediatr Int; 2021 Apr 20; 63(4):404-409. PubMed ID: 32856363
    [Abstract] [Full Text] [Related]

  • 16. Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.
    Li J, Wang P, Li X, Wang Q, Zhang J, Lin Y.
    Mediterr J Hematol Infect Dis; 2020 Apr 20; 12(1):e2020029. PubMed ID: 32395218
    [Abstract] [Full Text] [Related]

  • 17. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A, Gillard S, Spino M, Connelly J, Tricta F.
    Pharmacoeconomics; 2013 Sep 20; 31(9):807-22. PubMed ID: 23868464
    [Abstract] [Full Text] [Related]

  • 18. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients.
    Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H.
    Expert Rev Hematol; 2019 Nov 20; 12(11):997-1003. PubMed ID: 31486684
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H, Qin Y, Chen G, Zhao Y.
    Acta Haematol; 2019 Nov 20; 141(1):32-42. PubMed ID: 30504715
    [Abstract] [Full Text] [Related]

  • 20. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, Yesilipek A.
    Eur J Haematol; 2012 May 20; 88(5):431-8. PubMed ID: 22335829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.